Introduction Type-2 biologics allow for successful treatment of patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). Eosinophils have been established as a reliable biomarker of type-2 disease and enable the differentiation of inflammatory patterns in CRSwNP. Aim of this study was to evaluate, whether peripheral blood eosinophilia before initiation of therapy with type-2 biologics allows assesment of response to treatment in patients with CRSwNP.
No takes yet. Share an insight, caveat, or question.
Kotz et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: